Abstract: Compositions which contain an agonist substance of one or a number of receptors associated with a chlorine channel are useful for slackening and/or relaxing cutaneous tissue, and in particular for the purpose of treating wrinkles and fine lines of the skin. Such compositions can be administered topically or by injection. Preferred agonists include glycine, serine, taurine, .beta.-alanine, N-(benzyloxycarbonyl)glycine (Z-glycine), gamma-aminobutyric acid (GABA), isoguvacine, isonipecotic acid, 4,5,6,7-tetrahydroisoxazolo?5,4-c!pyrid-3(2H)-one, benzodiazepines, steroids, and barbiturates. The composition can additionally contain a retinoid and/or a hydroxy acid.

Abstract: Dermatological/pharmaceutical compositions, well suited for the therapeutic treatment of and/or alleviation of pain associated with at least one of the skin disorders, zona, poszoster, scald or burns, demodicidosis, skin ulcer, fibrosis, hypertrophic cicatrization and/or acne rosacea, comprise an effective substance P antagonist amount of at least one salt of yttrium, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, tin, zinc, manganese, cobalt, barium, strontium, or mixture thereof, in a dermatologically/pharmaceutically acceptable medium therefor.

Abstract: The invention relates to a composition, in particular a cosmetic composition, and more particularly one for dyeing keratin fibers, this composition containing at least one substance P antagonist in order to reduce or even eliminate the irritant effects of the dyes and/or pigments and/or dye precursors used during this dyeing. The substance P antagonist may form part of the dye composition itself or may be contained in a composition which is applied prior to the application of the dye composition.

Abstract: The invention relates to the use of a salt of an alkaline-earth metal in a cosmetic, pharmaceutical, veterinary and/or dermatological composition for treating, in particular, sensitive skins. It relates, in addition, to the use of a salt of an alkaline-earth metal for preventing and/or combating rosacea and/or skin irritation and/or dartre and/or pudic erythema and/or dysesthetic sensation and/or sensation of inflammation and/or pruritus of the skin and/or of the mucous membranes. The salt is in particular strontium nitrate or chloride.

Abstract: Topically applicable pharmaceutical/dermatological/cosmetic compositions well suited for the therapeutic treatment or care of sensitive human skin, hair, mucous membranes, nails and/or the scalp, in particular for reducing or avoiding the skin-irritant side effects of a variety of bioactive agents, for example the .alpha.-hydroxy and .beta.-hydroxy acids, comprise a therapeutically/cosmetically effective amount of at least one bradykinin antagonist.

Abstract: The invention relates to a therapeutic composition for topical application containing at least one product with an irritant side effect and a substance P antagonist for reducing or even eliminating the irritant effect of this product.It also relates to the use of a substance P antagonist for the preparation of a pharmaceutical composition for topical application containing at least one product with an irritant side effect for reducing or even eliminating the irritant effect of this product.The substance P antagonist may be a peptide compound or a nitrogen-containing compound or a nitrogen-, sulphur- or oxygen-containing heterocyclic compound.

Abstract: Cosmetic compositions, well suited for the permanent deformation of keratinous fibers, for example permanent waves for topical application to human hair, comprise at least one reducing agent and/or at least one oxidizing agent other than a peroxide or cresol, at least one of reducing and/or oxidizing agents normally eliciting a skin irritating side effect, and an effective skin irritant-attenuating/eliminating amount of at least one substance P antagonist and/or at least one CGRP antagonist, in a physiologically acceptable medium therefor.

Abstract: The present invention relates to the use of at least one extract from at least one non-photosynthetic filamentous bacterium as substance P antagonist in a cosmetic composition or for the preparation of a pharmaceutical composition. The invention also relates to the use of at least one extract from at least one non-photosynthetic filamentous bacterium in a cosmetic composition or for the preparation of a pharmaceutical composition intended for the treatment of disorders associated with an excess in the synthesis and/or in the release of substance P. The invention additionally relates to various compositions containing an extract from at least one non-photosynthetic filamentous bacterium and to a cosmetic treatment process.

Abstract: Cutaneous perspiration in a human subject is prevented and/or controlled by topically applying to the skin of an individual in need of such treatment, an effective antiperspirant amount of at least one substance P antagonist.

Abstract: The invention relates to the use of a substance P antagonist for the preparation of a pharmaceutical composition, especially for topical application, for treating skin reddening of neurogenic origin, and especially rosacea and pudic erythema.The substance P antagonist may be a peptide compound or a nitrogen-containing compound or a nitrogen-containing, sulphur-containing or oxygen-containing heterocyclic compound.

Abstract: A method for the treatment of acne and/or the effects of ageing, by administering, to a subject in need thereof, a composition containing an effective amount of at least one HMG-Coenzyme A-reductase inhibitor in a carrier that is selected from the group consisting of dermatologically acceptable carriers, cosmetically acceptable carriers, and mixtures thereof, and the compositions for performing the method are provided.

Abstract: The invention relates to the use of a substance P antagonist in or for the preparation of a cosmetic or pharmaceutical composition, in particular for topical application, for treating pruritus, ocular or palpebral pain and ocular or palpebral dysaesthesia. The cosmetic composition may be used for making up sensitive eyes or removing make-up therefrom.

Abstract: The invention relates to the use of an ethylenediamine derivative as a substance P antagonist and/or as a local analgesic in, or for the preparation of, a cosmetic or dermatological composition for treating sensitive skin-types. The invention relates in particular to the use of this derivative for preventing and/or combating skin irritations and/or dartres and/or erythema and/or dysaesthesic sensations and/or sensations of inflammation and/or pruritus of the skin and/or the mucous membranes including the eyes. The invention also relates to a composition containing a product having an irritant side effect and this derivative, so as to reduce this irritant effect or even to remove it altogether.

Abstract: The invention relates to the use of a substance P antagonist for the preparation of a pharmaceutical composition, in particular for topical application, for treating lichens, prurigo, pruriginous toxicoderma and severe pruritus of neurogenic origin.

Abstract: The invention relates to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha anlagonist in a cosmetic, pharmaceutical or dermatological composition for treating sensitive skins. It relates especially to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist for preventing and/or combating skin irritations and/or sores and/or erythema and/or dysaesthetic sensations and/or sensations of inflammation and/or pruritus and/or prickling and/or tingling and/or discomfort and/or tightness of the skin and/or mucosae. It also relates to a composition containing a histamine antagonist, an interleukin-1 anlagonist and/or a TNF alpha antagonist which limits or eliminates the irritant side-effects of certain products, and in particular of certain cosmetic, dermatological or pharmaceutical active agents.